Valeant Pharmaceuticals Intern… (NYSE:VRX)

Valeant Pharmaceuticals Gets Boost From FDA Update

Shares of Valeant Pharmaceuticals International Inc. (NYSE: VRX) saw a handy gain on Thursday after the company provided an update from the U.S. Food and Drug Administration (FDA). Specifically, the ...
Read Full Story »

Is This the Turnaround Valeant Pharma Has Been Waiting For?

Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported its second-quarter financial results before the markets opened on Tuesday. This stock is known for its fall from grace, trading above $250 per ...
Read Full Story »

Disney, Snap and More of the Top Earnings to Watch This Week

24/7 Wall St. has put together a preview of a few major companies scheduled to report their quarterly results this coming week. The Dow Jones Industrial Average has hit a ...
Read Full Story »

Valeant Pharmaceuticals Plans to Sell iNova Segment

Valeant Pharmaceuticals International Inc. (NYSE: VRX) shares made a solid gain on Thursday after the company announced the sale of its iNova Pharmaceutical business. Ultimately, Valeant will sell iNova for ...
Read Full Story »

Is Valeant for Real This Time?

When Valeant Pharmaceuticals International Inc. (NYSE: VRX) released its first-quarter financial results before the markets opened on Tuesday, it totally shocked investors. This stock has trended lower for a long ...
Read Full Story »

How Valeant Earnings Beat Estimates

Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported first-quarter 2017 results before markets opened Tuesday. The company reported quarterly diluted earnings per share (EPS) of $1.79 and revenues of $2.11 billion. ...
Read Full Story »

Disney, Snap, Whole Foods and More Key Earnings Reports Coming This Week

24/7 Wall St. has put together a preview of a few major companies scheduled to report their quarterly results this coming week. The broad markets have been pushing closer to ...
Read Full Story »

Valeant Still Has a Long Way to Go on Paying Down Its Debt

Valeant Pharmaceuticals International Inc. (NYSE: VRX) is a company that many health care and activist investors alike wish they never had heard of. On Monday, May 1, 2017, its shares were ...
Read Full Story »

Rite Aid, DryShips Stumble into Monday’s 52-Week Low Club

April 24, 2017: Here are four stocks trading with relatively heavy volume among 57 equities making new 52-week lows in Monday's session. On the NYSE, advancers led decliners by more ...
Read Full Story »

Mattel, Valeant Stagger into Friday’s 52-Week Low Club

April 21, 2017: Here are four stocks trading with relatively heavy volume among 58 equities making new 52-week lows in Friday's session. On the NYSE, decliners led advancers by about ...
Read Full Story »

Rite Aid, Valeant Tumble into Thursday’s 52-Week Low Club

April 20, 2017: Here are four stocks trading with relatively heavy volume among 54 equities making new 52-week lows in Thursday's session. On the NYSE, advancers led decliners by about ...
Read Full Story »

Rite Aid, Frontier Communications Slip into Wednesday’s 52-Week Low Club

April 19, 2017: Here are four stocks trading with relatively heavy volume among 71 equities making new 52-week lows in Wednesday's session. On the NYSE, decliners led advancers by about ...
Read Full Story »

Valeant, Arena Pharmaceuticals in Tuesday’s 52-Week Low Club

April 18, 2017: Here are four stocks trading with relatively heavy volume among 85 equities making new 52-week lows in Tuesday's session. On the NYSE, decliners led advancers by about ...
Read Full Story »

Valeant, QEP Resources Slide into Monday’s 52-Week Low Club

April 17, 2017: Here are four stocks trading with relatively heavy volume among 75 equities making new 52-week lows in Monday's session. On the NYSE, advancers led decliners by about ...
Read Full Story »

Valeant, Sorrento Pharmaceuticals Tumble into Thursday’s 52-Week Low Club

April 13, 2017: Here are four stocks trading with relatively heavy volume among 75 equities making new 52-week lows in Thursday's session. On the NYSE, decliners led advancers by more ...
Read Full Story »